Five-year safety and immunogenicity of GlaxoSmithKline’s candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia

RTS,S is a pre-erythrocytic malaria vaccine candidate antigen based on the circumsporozoite surface protein of Plasmodium falciparum fused to HBsAg, incorporating a novel Adjuvant System (AS02). The first field efficacy of RTS,S/AS02 against infection was demonstrated in a trial initiated in The Gam...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Bojang, Kalifa, Milligan, Paul, Pinder, Margaret, Doherty, Tom, Leach, Amanda, Ofori-Anyinam, Opokua, Lievens, Marc, Kester, Kent, Schaecher, Kurt, Ballou, W. Ripley, Cohen, Joe
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3787299/
https://ncbi.nlm.nih.gov/pubmed/19276646
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars